Enliven Therapeutics (ELVN) Change in Account Payables (2019 - 2026)
Enliven Therapeutics (ELVN) reported Change in Account Payables of -$519000.0 for Q1 2026, down 335.91% on a YoY basis from $220000.0 in Q1 2025, and down 162.68% sequentially from $828000.0 in Q4 2025.
Enliven Therapeutics (ELVN) Change in Account Payables (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Change in Account Payables data on file, last reported at -$519000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 335.91% year-over-year to -$519000.0; the trailing twelve-month figure through Mar 2026 stood at $78000.0 (up 106.93% YoY), and the FY2025 full-year result was $817000.0, up 0.86% from the prior year.
- Change in Account Payables retreated to -$519000.0 in Q1 2026, from $828000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q1 2024 to a low of -$1.6 million in Q2 2024.
- A 5-year average of -$43000.0 and a median of $18000.0 in 2022 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables jumped 1005.33% in 2022 and sank 5438.89% in 2023, its largest moves.
- Tracing ELVN's Change in Account Payables over 5 years: stood at $18000.0 in 2022, then slumped by 5438.89% to -$961000.0 in 2023, then soared by 133.61% to $323000.0 in 2024, then soared by 156.35% to $828000.0 in 2025, then sank by 162.68% to -$519000.0 in 2026.
- Business Quant data shows ELVN's Change in Account Payables at -$519000.0 in Q1 2026, $828000.0 in Q4 2025, and -$1.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - | - |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 16.86 Mn |
| 10 | Enliven Therapeutics | 3.45 Bn | 3.00 Bn | - | -519,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -519,000.00 |
| Mar 31, 2026 | -519,000.00 |
| Dec 31, 2025 | 828,000.00 |
| Dec 31, 2025 | 828,000.00 |
| Sep 30, 2025 | -1.02 Mn |
| Sep 30, 2025 | -1.02 Mn |
| Jun 30, 2025 | 789,000.00 |
| Jun 30, 2025 | 789,000.00 |
| Mar 31, 2025 | 220,000.00 |
| Mar 31, 2025 | 220,000.00 |
| Dec 31, 2024 | 323,000.00 |
| Dec 31, 2024 | 323,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Sep 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | -961,000.00 |
| Dec 31, 2023 | -961,000.00 |